- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
April 29, 2024Robins Kaplan Mourns Death of New York Associate Waleed Abbasi
-
April 29, 2024Robins Kaplan Secures $7.75 Million Verdict in Aerosol Dust Remover Abuse Case
-
April 23, 2024David Martinez Recognized Among Top 100 Lawyers in Los Angeles by LA Business Journal
-
May 9, 2024Property Insurance Claims Group 2024 Conference
-
May 20, 2024The Present and Future of DEI
-
May 23, 202414th Annual Disability Justice Seminar
-
April 30, 2024A World Without Non-Competes: Protecting Confidential Information and Trade Secrets Following the FTC's Ban
-
First QuarterGENERICally Speaking: A Hatch-Waxman Litigation Bulletin
-
March 2024e-Commerce: Pitfalls and Protections
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Consumer Alert: Digitek Heart Failure Medications Recalled - A Serious Risk of Injury or Death to the Patient
May 21, 2008
On April 25, 2008 Actavis Totowa LLC (formerly known as Amide Pharmaceutical, Inc.) announced the Class I nationwide recall of all strengths of oral Digitek tablets, which is a brand name for digoxin tablets, USP 0.125 mg and 0.25 mg.[1] The products are manufactured by Actavis Totawa LLC, a division of the international generic pharmaceutical company Actavis Group, and distributed by Mylan Pharmaceuticals, Inc. under a "Bertek" label and by UDL Laboratories, Inc. under a "UDL" label.[2]
The Reason Behind the Nationwide Recall:
Digitek is used to treat heart failure and abnormal heart rhythms.[3] Unfortunately, all lots of the drug have been voluntarily recalled because tablets may be double the appropriate thickness and thus tablets may contain twice the approved level of the active ingredient.[4] The existence of double-strength tablets poses a risk of toxicity in patients with renal failure and those who are on dialysis.[5]
How the Recalled Medications Can Injure Patients:
Too high a dosage of Digitek can cause Digitalis toxicity, which can lead to nausea, vomiting, dizziness, low blood pressure, cardiac instability, bradycardia and even death.[6] The recall was initiated after several reports of injuries and illnesses have been received.[7]
Attorneys at Robins, Kaplan, Miller & Ciresi L.L.P. are currently investigating claims related to Digitek. If you or someone you know has been injured or killed following use of Digitek and you wish to consult with a lawyer, please call Kate Jaycox at 1-800-553-9910 or 612-349-8500 or e-mail us by clicking on this link: contact us.
[2] Press Releases, Actavis Totowa (formerly known as Amide Pharmaceutical, Inc.) recalls all lots of Bertek and UDL Laboratories Digitek (digoxin tablets, USP) as a precaution, dated April 25, 2008, available at http://www.actavis.us/en/media+center/newsroom/articles/digitek+recall.htm or at Recall - - Firm Press Release, http://www.fda.gov/oc/po/firmrecalls/actavis04_08.html.
[3] Id.
[4] Id.
[5] Id.
[6] Id.
[7] Id.
The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.
Related Professionals
Kate E. Jaycox
Partner
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.